[go: up one dir, main page]

MA42776B1 - Composés utiles pour l'inhibition du ror-gamma-t - Google Patents

Composés utiles pour l'inhibition du ror-gamma-t

Info

Publication number
MA42776B1
MA42776B1 MA42776A MA42776A MA42776B1 MA 42776 B1 MA42776 B1 MA 42776B1 MA 42776 A MA42776 A MA 42776A MA 42776 A MA42776 A MA 42776A MA 42776 B1 MA42776 B1 MA 42776B1
Authority
MA
Morocco
Prior art keywords
ror
inhibiting
compounds useful
gamma
pharmaceutical compositions
Prior art date
Application number
MA42776A
Other languages
English (en)
Inventor
John Richard Morphy
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA42776B1 publication Critical patent/MA42776B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne de nouveaux inhibiteurs du ror-gamma-t et des compositions pharmaceutiques associées.
MA42776A 2015-09-09 2016-09-06 Composés utiles pour l'inhibition du ror-gamma-t MA42776B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562215929P 2015-09-09 2015-09-09
PCT/US2016/050374 WO2017044410A1 (fr) 2015-09-09 2016-09-06 Composés utiles pour l'inhibition du ror-gamma-t
EP16766765.8A EP3347360B1 (fr) 2015-09-09 2016-09-06 Composés utiles pour l'inhibition du ror-gamma-t

Publications (1)

Publication Number Publication Date
MA42776B1 true MA42776B1 (fr) 2020-02-28

Family

ID=56940418

Family Applications (1)

Application Number Title Priority Date Filing Date
MA42776A MA42776B1 (fr) 2015-09-09 2016-09-06 Composés utiles pour l'inhibition du ror-gamma-t

Country Status (41)

Country Link
US (1) US9598431B1 (fr)
EP (1) EP3347360B1 (fr)
JP (1) JP6282789B1 (fr)
KR (1) KR102048780B1 (fr)
CN (1) CN108026112B (fr)
AR (1) AR105821A1 (fr)
AU (1) AU2016318593B2 (fr)
BR (1) BR112018001451B1 (fr)
CA (1) CA2994732C (fr)
CL (1) CL2018000558A1 (fr)
CO (1) CO2018002440A2 (fr)
CR (1) CR20180089A (fr)
CY (1) CY1122287T1 (fr)
DK (1) DK3347360T3 (fr)
DO (1) DOP2018000066A (fr)
EA (1) EA033882B1 (fr)
EC (1) ECSP18018793A (fr)
ES (1) ES2760992T3 (fr)
HK (1) HK1249901B (fr)
HR (1) HRP20192235T1 (fr)
HU (1) HUE047950T2 (fr)
IL (1) IL257202B (fr)
JO (1) JO3638B1 (fr)
LT (1) LT3347360T (fr)
MA (1) MA42776B1 (fr)
MD (1) MD3347360T2 (fr)
MX (1) MX374654B (fr)
MY (1) MY195903A (fr)
NZ (1) NZ739518A (fr)
PE (1) PE20181274A1 (fr)
PH (1) PH12018500504A1 (fr)
PL (1) PL3347360T3 (fr)
PT (1) PT3347360T (fr)
RS (1) RS59655B1 (fr)
SI (1) SI3347360T1 (fr)
SV (1) SV2018005647A (fr)
TN (1) TN2018000057A1 (fr)
TW (1) TWI597284B (fr)
UA (1) UA118824C2 (fr)
WO (1) WO2017044410A1 (fr)
ZA (1) ZA201800515B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3589637T3 (da) 2017-03-02 2021-06-14 Lilly Co Eli Forbindelser, der er anvendelige til inhibering af ROR-GAMMA-T
RS61788B1 (sr) * 2017-03-02 2021-06-30 Lilly Co Eli Jedinjenja korisna za inhibiciju rorγt
WO2018193297A1 (fr) 2017-04-21 2018-10-25 Cadila Healthcare Limited Nouveaux composés utilisés en tant que modulateurs de ror-gamma
JP2020142989A (ja) * 2017-06-21 2020-09-10 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 イミダゾール誘導体及びそれを含有する医薬
WO2022095971A1 (fr) * 2020-11-06 2022-05-12 上海医药集团股份有限公司 Composé spiro hétérocyclique, son procédé de préparation et son utilisation
WO2022122740A1 (fr) 2020-12-07 2022-06-16 Diaccurate Inhibiteurs de ror-gamma pour le traitement du cancer dépendant de ror-gamma
WO2023232870A1 (fr) 2022-05-31 2023-12-07 Immunic Ag Modulateurs de rorg/rorgt pour le traitement d'infections virales de type covid-19

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016913A1 (fr) * 2003-08-19 2005-02-24 Pfizer Japan, Inc. Composes de tetrahydroisoquinoline ou d'isochroman en tant que ligands du recepteur orl-1 pour le traitement de la douleur et des troubles du systeme nerveux central
JP3790250B2 (ja) * 2004-01-16 2006-06-28 新日鐵化学株式会社 両面導体ポリイミド積層体の連続製造方法
SI2501704T1 (sl) * 2009-11-16 2013-11-29 Eli Lilly Company Spojine spiropiperidina kot antagonisti oral-1 receptorja
UA107943C2 (xx) * 2009-11-16 2015-03-10 Lilly Co Eli Сполуки спіропіперидину як антагоністи рецептора orl-1
WO2011069063A2 (fr) * 2009-12-04 2011-06-09 Sunovion Pharmaceuticals, Inc. Composés multicycliques et leurs procédés d'utilisation
TWI582096B (zh) * 2011-12-06 2017-05-11 美國禮來大藥廠 用於酒精依賴及濫用處理之４',５'－二氫螺［哌啶－４,７'－噻吩并[２，３－c]哌喃］化合物
RU2014149136A (ru) * 2012-05-08 2016-07-10 Мерк Шарп И Доум Корп. ТЕТРАГИДРОНАФТИРИДИНОВЫЕ И РОДСТВЕННЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ RORγ АКТИВНОСТИ И ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ
CN107007597A (zh) * 2012-05-31 2017-08-04 菲尼克斯药品股份公司 作为孤儿核受体RORγ调节物的经甲酰胺或磺酰胺取代的噻唑及相关衍生物的制药用途
WO2014026328A1 (fr) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. Composés d'indazole et d'indole à substitution 3-cyclohexényle en tant qu'inhibiteurs de rorgammat et leurs utilisations
EP2991994B1 (fr) 2013-05-01 2018-08-15 Vitae Pharmaceuticals, Inc. Inhibiteurs du ror-gamma à base de thiazolopyrrolidine
EP3027616B1 (fr) 2013-07-30 2018-01-10 Boehringer Ingelheim International GmbH Composés d'azaindole à titre de modulateurs de rorc
WO2015101928A1 (fr) * 2013-12-31 2015-07-09 Aurigene Discovery Technologies Limited Dérivés de thiophène et de thiazole fusionnés utilisés en tant que modulateurs gamma ror

Also Published As

Publication number Publication date
EA201890364A1 (ru) 2018-08-31
NZ739518A (en) 2019-06-28
EA033882B1 (ru) 2019-12-05
EP3347360A1 (fr) 2018-07-18
BR112018001451A2 (pt) 2018-09-11
CA2994732C (fr) 2020-06-30
PL3347360T3 (pl) 2020-04-30
SI3347360T1 (sl) 2019-12-31
DOP2018000066A (es) 2018-03-30
AU2016318593B2 (en) 2018-10-04
ECSP18018793A (es) 2018-04-30
MY195903A (en) 2023-02-27
CN108026112B (zh) 2020-04-10
IL257202A (en) 2018-03-29
CA2994732A1 (fr) 2017-03-16
KR20180031777A (ko) 2018-03-28
KR102048780B1 (ko) 2019-11-27
CR20180089A (es) 2018-02-27
US9598431B1 (en) 2017-03-21
HUE047950T2 (hu) 2020-05-28
WO2017044410A1 (fr) 2017-03-16
MD3347360T2 (ro) 2020-03-31
US20170066781A1 (en) 2017-03-09
EP3347360B1 (fr) 2019-10-23
HK1249901B (en) 2020-06-19
CN108026112A (zh) 2018-05-11
CO2018002440A2 (es) 2018-07-10
DK3347360T3 (da) 2020-01-02
TWI597284B (zh) 2017-09-01
TN2018000057A1 (en) 2019-07-08
JP2018507203A (ja) 2018-03-15
LT3347360T (lt) 2020-01-27
TW201722964A (zh) 2017-07-01
ZA201800515B (en) 2019-06-26
HRP20192235T1 (hr) 2020-03-20
MX374654B (es) 2025-03-06
AU2016318593A1 (en) 2018-02-15
RS59655B1 (sr) 2020-01-31
PH12018500504A1 (en) 2018-09-24
PT3347360T (pt) 2020-01-07
JO3638B1 (ar) 2020-08-27
PE20181274A1 (es) 2018-08-03
CY1122287T1 (el) 2020-11-25
UA118824C2 (uk) 2019-03-11
IL257202B (en) 2020-02-27
SV2018005647A (es) 2018-07-23
MX2018002898A (es) 2018-06-18
ES2760992T3 (es) 2020-05-18
AR105821A1 (es) 2017-11-15
JP6282789B1 (ja) 2018-02-21
CL2018000558A1 (es) 2018-08-10
BR112018001451B1 (pt) 2023-10-10

Similar Documents

Publication Publication Date Title
MA42776B1 (fr) Composés utiles pour l'inhibition du ror-gamma-t
JOP20200122B1 (ar) مركبات مفيدة لتثبيط cdk7
MX2018001990A (es) Composiciones que comprenden un inhibidor de p13k y un inhibidor de hdac.
GEAP202015005A (en) Diacylglycerol acyltransferase 2 inhibitors
PH12017501888A1 (en) Bromodomain inhibitor
MX2018005600A (es) Composiciones farmaceuticas y metodos para la inhibicion de indolamina 2,3-dioxigenasa e indicaciones para ello.
MA41013A (fr) Compositions comprenant des souches bactériennes
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
PH12018500177A1 (en) Compositions useful for treating disorders related to kit and pdfgr
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
CU20180134A7 (es) Derivados de piridiniltriazol sustituidos con amida útiles para tratar enfermedades renales y cardiovasculares
MX393993B (es) Inhibidores de bromodominio
EA201790170A1 (ru) Терапевтические соединения-ингибиторы
MA39172B1 (fr) Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines
MX380250B (es) Compuestos farmacéuticos inhibidores de cinasa chk-1.
MA39025B1 (fr) Pipéridyl-éthyl-pyrimidine substituée utilisée comme inhibiteur de la ghréline o-acyl transférase
EP2968316A4 (fr) Nouveaux composés et compositions pour l'inhibition de fasn
TN2017000213A1 (en) 5-[(piperazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as adamts inhibitors for the treatment of osteoarthritis
PH12017500841A1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
EA201691397A1 (ru) Хинолиновые ингибиторы киназы
MX373320B (es) Compuestos inhibidores de pde2.
EP3277757A4 (fr) Compositions pour l'inhibition de corrosion
MA40366A (fr) Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines
JOP20190262B1 (ar) مثبطات بيرازول magl
EP3541379A4 (fr) Compositions pour le traitement de l'hypertension